Aktienanalyse zu NanoViricides, Inc (NNVC)NNVCNanoViricides, Inc

NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

NanoViricides Inc is a good buy right now due to its current price of $1.35, which is significantly below the analyst price target of $6, indicating a potential upside of over 350%. Additionally, the recent approval for a Phase II trial in the Democratic Republic of Congo for their antiviral drug NV-387 highlights the company's growth potential in the biotech sector. However, investors should be cautious of the company's negative earnings trend, with a net income loss of $2,223,399 reported for Q4 2026, which remains a significant risk.